Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years

Unknown 300 enrolled Jianxiang Wang

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the escalation dosage of Daunorubicin and cytarabine is effective and safety in the treatment of older adult Chinese acute myeloid leukemia（AML） patients aged 55 to 65 years.

Timeline

Start: 2015-04
Primary completion: 2018-05
Completion: 2021-05

Publications

Zhou C, Li L, Li Y, Liu K, Liu Y, Lin D, Gong B, Zhang G, Gong X, Fang Q, Liu B, Qiu S, Wang Y, Wei H, Mi Y, Wang J. Daunorubicin-45 Vs. Daunorubicin-60 for Induction in Intermediate-Age Patients of AML: Results From a Randomized Trial. Cancer Sci. 2026 Jun;117(6):1690-1700. doi: 10.1111/cas.70383. Epub 2026 Apr 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cytarabine	Small molecule	100 mg/m2	—
Subject	Cytarabine	Small molecule	1 g	—
Subject	Daunorubicin	Small molecule	45 mg/m2	—
Subject	Daunorubicin	Small molecule	60 mg/m2	—
Background	Aclacinomycin	Unknown	20 mg	—

Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years

Summary

Timeline

Publications

Drugs

Indications